Prescription drug · ANDA
Cytarabine NDC 63323-120
Cytarabine 100 mg/mL · Injection, Solution · Intrathecal, Intravenous, Subcutaneous · Fresenius Kabi USA, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 63323-120-20 | 6332301202063323012020 | 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-120-20) / 20 mL in 1 VIAL, SINGLE-DOSEMarketed from Nov 29, 2004 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Cytarabine
- Generic name (nonproprietary)
- cytarabine
- Active ingredients
- Cytarabine — 100 mg/mL
- Dosage form
- Injection, Solution
- Route
- Intrathecal, Intravenous, Subcutaneous
- Labeler
- Fresenius Kabi USA, LLCNDC labeler code 63323
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 076512
- Marketing start
- Listing expires
- Other FDA classes
- Nucleic Acid Synthesis Inhibitors (Mechanism)
- Identifiers
- Product ID 63323-120_648872de-503c-4140-9c0f-94f772177ac3SPL ID 648872de-503c-4140-9c0f-94f772177ac3
- Pharmacologic class
- Nucleoside Metabolic Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N463323012020followed by a unit qualifier and the quantityPackage 63323-0120-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
The FDA listing for this product does not reference a label (SPL) set.
About NDC 63323-120
- What is NDC 63323-120?
- 63323-120 is the product NDC for Cytarabine, Cytarabine 100 mg/mL injection, solution, listed with the FDA by Fresenius Kabi USA, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Cytarabine.
- What is the active ingredient?
- Cytarabine.
- Who is the labeler?
- Fresenius Kabi USA, LLC, NDC labeler code 63323. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Cytarabine?
- 13 other product NDCs are listed under this name. See all Cytarabine NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Cytarabine products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Cytarabine | Cytarabine 100 mg/mL | Injection, SolutionIntrathecal, Intravenous, Subcutaneous | Hospira, Inc. | 61703-155 | 61703-0155-01 |
| cytarabine | Cytarabine 100 mg/mL | Injection, SolutionIntrathecal, Intravenous, Subcutaneous | Sagent Pharmaceuticals | 25021-223 | 25021-0223-20 |
| cytarabine | Cytarabine 20 mg/mL | Injection, SolutionIntrathecal, Intravenous, Subcutaneous | Sagent Pharmaceuticals | 25021-229 | 25021-0229-05 |
| Cytarabine | Cytarabine 20 mg/mL | Injection, SolutionIntravenous, Subcutaneous | Meitheal Pharmaceuticals Inc. | 71288-169 | 71288-0169-25 |
| Cytarabine | Cytarabine 20 mg/mL | Injection, SolutionIntrathecal, Intravenous, Subcutaneous | Meitheal Pharmaceuticals Inc. | 71288-108 | 71288-0108-06 |
| Cytarabine | Cytarabine 100 mg/mL | Injection, SolutionIntrathecal, Intravenous, Subcutaneous | Gland Pharma Limited | 68083-337 | 68083-0337-01 |
| Cytarabine | Cytarabine 20 mg/mL | Injection, SolutionIntrathecal, Intravenous, Subcutaneous | Gland Pharma Limited | 68083-343 | 68083-0343-05 |
| Cytarabine | Cytarabine 2 g/20mL | Injection, SolutionIntrathecal, Intravenous, Subcutaneous | Meitheal Pharmaceuticals Inc. | 71288-109 | 71288-0109-20 |
| Cytarabine | Cytarabine 20 mg/mL | Injection, SolutionIntravenous, Subcutaneous | Meitheal Pharmaceuticals Inc. | 71288-168 | 71288-0168-50 |
| Cytarabine | Cytarabine 100 mg/mL | Injection, SolutionIntrathecal, Intravenous, Subcutaneous | Hospira, Inc. | 61703-319 | 61703-0319-22 |